Familial nephropathic systemic amyloidosis caused by apolipoprotein AI variant Arg26.
A point mutation in the apolipoprotein AI (apoAI) gene causing autosomal dominant non-neuropathic systemic amyloidosis is described in a previously unreported Canadian family of British origin with five affected individuals in three generations. Amyloid deposits in the renal biopsy from the proband, a 31-year-old female presenting with hypertension and renal failure, stained immunospecifically with antiserum to apoAI. The plasma of all family members with amyloidosis contained both wild-type apoAI and a variant bearing one additional positive charge. Sequencing of the apoAI gene demonstrated that the proband was a heterozygote for a single base substitution in exon 3, changing codon 26 from GGC(Gly) to CGC(Arg). Concordance of the mutant allele with the presence of variant plasma apoAI and clinical features of amyloidosis was demonstrated. This is the third family in which this amyloidotic mutation has been described, but the distribution of amyloid deposits and their clinical effects are clearly determined by other genetic and/or environmental factors.
Vigushin
D M
DM
Immunological Medicine Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Gough
J
J
Allan
D
D
Alguacil
A
A
Penner
B
B
Pettigrew
N M
NM
Quinonez
G
G
Bernstein
K
K
Booth
S E
SE
Booth
D R
DR
D000328:Adult; D000686:Amyloidosis / Q000235:genetics* / Q000378:metabolism; D016632:Apolipoprotein A-I / Q000235:genetics* / Q000378:metabolism; D001483:Base Sequence; D005091:Exons / Q000235:genetics; D005190:Family; D005260:Female; D005784:Gene Amplification; D006579:Heterozygote; D006801:Humans; D007150:Immunohistochemistry; D007668:Kidney / Q000378:metabolism; D007674:Kidney Diseases / Q000235:genetics* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D010375:Pedigree; D017354:Point Mutation; D017422:Sequence Analysis, DNA
D016632:Apolipoprotein A-I